Data Sheet (Cat.No.T1780)



Parecoxib

Chemical Properties


CAS No.: 198470-84-7

Formula: C19H18N2O4S

Molecular Weight: 370.42

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

| Description | Parecoxib (SC 69124) is an effective and selective COX-2 inhibitor. |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Targets(IC50) | COX |
| In vivo | Parecoxib, a selected cyclooxygenase-2 inhibitor, ameliorates neurologic deficits in the behavior studies and brain damage, including neuronal death, and brain edema in the MCP-1 and NeuN immunostaining in rats subjected to SAH(Subarachnoid Hemorrhage). Parecoxib is able to reduce early COX2 expression via inhibiting cJNK (p55) expression (dose-dependently), reduce IL-1 β , IL-6 and MCP-1(at 2000 ug/kg/day at the time point of 24hr and 72hr after the induction of SAH), IL-8 (of the dosage of 2000 ug/kg/day at 24hr after the induction of SAH), and also reduce cleaved caspase-1 (at 1000 and 2000 |
| | ug/kg/day) and Caspase-9a (at 2000 ug/kg/day). Parecoxib reduces the NMDAR-1, and NMDAR-2a (at 1000 and 2000 ug/kg) after the induction of SAH[2]. |

Solubility Information

| Solubility | Ethanol: 2 mg/mL (5.4 mM), Sonication is recommended. | |
|------------|-----------------------------------------------------------------|--|
| | H2O: < 1 mg/mL (insoluble or slightly soluble), | |
| | DMSO: 50 mg/mL (134.98 mM), Sonication is recommended. | |
| | (< 1 mg/ml refers to the product slightly soluble or insoluble) | |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 2.6996 mL | 13.4982 mL | 26.9964 mL |
| 5 mM | 0.5399 mL | 2.6996 mL | 5.3993 mL |
| 10 mM | 0.270 mL | 1.3498 mL | 2.6996 mL |
| 50 mM | 0.054 mL | 0.270 mL | 0.5399 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Page 1 of 2 www.targetmol.com

Reference

Meunier A, et al. Arch Orthop Trauma Surg. 2006, 126(7):433-6. Chih-Zen Chang, et al. Journal of Neurology & Neurophysiology. 2015.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com